Fontem Ventures supports claims from the first cochrane review on EVPS29.01.15
Britain’s leading EVP (electronic vaping product) producer, Fontem Ventures, welcomes the first study by the Cochrane review,
LONDON, December 17 2014 – Britain’s leading EVP (electronic vaping product) producer, Fontem Ventures, welcomes the first study by the Cochrane review, which demonstrates the positive impact EVPs can have on smoking reduction or cessation for regular tobacco users.
Professor Peter Hajek, a review author from Queen Mary University of London, explained that although the number of trials were small, the results were certainly encouraging. The study shows that 9% of smokers who use EVPs were able to stop smoking for up to a year, compared to 4% of smokers who used non-nicotine devices. Additionally, 38% of EVP users managed to halve the number of traditional cigarettes they smoked, compared to 28% of those users who used a placebo device.
Marc Michelsen, Director of Communications and Public Affairs at Fontem Ventures said: “Fontem Ventures welcomes this latest contribution to our understanding of the impact of EVPs on the use of traditional tobacco products. Our consumer research shows many and varied reasons why smokers choose EVPs – and that does include, in some cases, a desire to reduce or even completely stop their smoking habit. .
“We agree with the study’s review authors that much more research needs to be undertaken to study the long-term impact of EVPs. Nevertheless, EVPs offer a real alternative to smoking tobacco for those wishing to enjoy nicotine in a way that better suits their life-style today. Moreover, there is a growing consensus among respected organisations and campaigners in the public health field, including Action on Smoking and Health (ASH), that EVPs as an alternative to tobacco could deliver a significant public health benefit.”
ASH in a statement has also welcomed the latest results from the Cochrane review.